The Journal of Urology
Volume 182, Issue 4 , Pages 1306-1312 , October 2009

Fibrin Clot Inhibitor Medication and Efficacy of Bacillus Calmette-Guerin for Bladder Urothelial Cancer

  • Stephen A. Boorjian

      Affiliations

    • Section of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
    • Corresponding Author InformationCorrespondence: 8 Huntingdon Pike, Rockledge, Pennsylvania 19046 (telephone: 215-728-2468; FAX: 215-214-1734)
    • ,
  • Ryan K. Berglund

      Affiliations

    • Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Alexandra C. Maschino

      Affiliations

    • Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Caroline J. Savage

      Affiliations

    • Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Harry W. Herr

      Affiliations

    • Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York

Received 27 January 2009

References 

  1. Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13:1404
  2. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124
  3. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325:1205
  4. Ratliff TL, Palmer JO, McGarr JA, et al. Intravesical bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guérin. Cancer Res. 1987;47:1762
  5. Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol. 1988;139:410
  6. Kavoussi LR, Brown EJ, Ritchey JK, et al. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. J Clin Invest. 1990;85:62
  7. Hudson MA, Brown EJ, Ritchey JK, et al. Modulation of fibronectin-mediated bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 1991;51:3726
  8. Hudson MA, Yuan JJ, Catalona WJ, et al. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol. 1990;144:1362
  9. P'ng KB, Walshh MD, Seymour GJ, et al. The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guérin efficacy for superficial bladder cancer. Aust N Z J Surg. 1993;63:127
  10. Witjes JA, Van Der Meijden AP, Doesburg W, et al. Influence of fibrin clot inhibitors on the efficacy of intravesical bacillus Calmette-Guérin in the treatment of superficial bladder cancer. Eur Urol. 1993;23:366
  11. Gee JR, Jarrard DF, Bruskewitz RC, et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. BJU Int. 2008;103:736
  12. El-Demiry MI, Smith G, Ritchie AW, et al. Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol. 1987;60:543
  13. Pan CW, Shen ZJ, Ding GQ. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study. J Urol. 2008;179:1307
  14. Berglund RK, Savage CJ, Vora KC, et al. An analysis of the effect of statin use on the efficacy of bacillus Calmette-Guerin treatment for transitional cell carcinoma of the bladder. J Urol. 2008;180:1297
  15. Bartolucci AA, Howard G. Meta-analysis of data from six preliminary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98:746
  16. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA. 2004;292:1867
  17. See WA, Chapmann PH. Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. J Urol. 1987;138:182
  18. See WA, Miller JS, Williams RD. Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. Cancer Res. 1989;49:5414
  19. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 1999;59:5647
  20. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60:5599
  21. Dovedi SJ, Kirby JA, Atkins H, et al. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 2005;174:332
  22. Badalament RA, Herr HW, Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol. 1987;5:441

 Study received institutional review board approval.

PII: S0022-5347(09)01495-5

doi: 10.1016/j.juro.2009.06.026

The Journal of Urology
Volume 182, Issue 4 , Pages 1306-1312 , October 2009

Article Tools

* Image Usage & Resolution